Amyloid-β 1–42 (Aβ1–42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer’s disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1–42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1–42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1–42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.
SimonsenAH, HerukkaSK, AndreasenN, BaldeirasI, BjerkeM, BlennowK, EngelborghsS, FrisoniGB, GabryelewiczT, GalluzziS, HandelsR, KrambergerMG, KulczynskaA, MolinuevoJL, MroczkoB, NordbergA, OliveiraCR, OttoM, RinneJO, RotU, SakaE, SoininenH, StruyfsH, SuardiS, VisserPJ, WinbladB, ZetterbergH, WaldemarG (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement13, 274–284.
2.
del CampoM, MollenhauerB, BertolottoA, EngelborghsS, HampelH, SimonsenAH, KapakiE, KruseN, Le BastardN, LehmannS, MolinuevoJL, ParnettiL, Perret-LiaudetA, Saez-ValeroJ, SakaE, UrbaniA, VanmechelenE, VerbeekM, VisserPJ, TeunissenC (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: An update. Biomark Med6, 419–430.
3.
WillemseEAJ, van UffelenKWJ, van der FlierWM, TeunissenCE (2017) Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Abeta1-42, T-tau, and P-tau values. Alzheimers Dement (Amst)8, 45–50.
4.
TijmsBM, WillemseEAJ, ZwanMD, MulderSD, VisserPJ, van BerckelBNM, van der FlierWM, ScheltensP, TeunissenCE (2018) Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-beta 1-42 analysis results. Clin Chem64, 576–585.
5.
SchindlerSE, SutphenCL, TeunissenC, McCueLM, MorrisJC, HoltzmanDM, MulderSD, ScheltensP, XiongC, FaganAM (2018) Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. Alzheimers Dement14, 62–70.
6.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
7.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFR, VisserPJ, Amyloid Biomarker Study G, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBN, BibeauK, BlennowK, BrooksDJ, van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, ForsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gomez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KohlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, de LeonM, LisettiV, LleoA, MadsenK, MaierW, MarcussonJ, MattssonN, de MendoncaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MollergardHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIH, RamiL, Resende de OliveiraC, RinneJO, RodrigueKM, Rodriguez-RodriguezE, RoeCM, RotU, RoweCC, RutherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchroderJ, SchutteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJ, van Waalwijk van DoornLJ, WaldemarG, WallinA, WallinAK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
10.
Algeciras-SchimnichA, BrunsDE, BoydJC, BryantSC, La FortuneKA, GrebeSK (2013) Failure of current laboratory protocols to detect lot-to-lot reagent differences: Findings and possible solutions. Clin Chem59, 1187–1194.
